Yahoo Finance19d
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...
Medscape7d
Age-Related Macular Degeneration Highlights From AAO 2024
Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...
PR Newswire18d
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...
Morningstar19d
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Investing17d
Citi reiterates Apellis stock as a 'BUY' on transformative pegcetacoplan data
The endorsement follows the company's presentation at the American Society of Nephrology (ASN) where they shared additional Phase 3 data for their drug pegcetacoplan in the treatment of C3 ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...